Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2013/2014 in People 18 Years of Age and Above
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2018
Price : $35 *
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 16 Nov 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2013-000855-42).
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.